Prostate Cancer Coverage from Every Angle


ASCO 2024: Can Self-Help Programs Reduce Adverse Effects of Androgen-Deprivation Therapy?
ASCO 2024: Choosing Between Bipolar Androgen Therapy and Enzalutamide in Metastatic Prostate Cancer
ASCO 2024: Is There a Role for Metformin in Treating Low-Risk Prostate Cancer?
ASCO 2024: Adding Cabazitaxel to Treatment Regimen in Castration-Resistant Prostate Cancer
ASCO 2024: Can LuPSMA Improve Quality of Life in Patients With Metastatic Prostate Cancer?
Advances in Identifying Biomarkers in Prostate Cancer
Research Team Sees Urine as Key to Noninvasive Prostate Cancer Detection
Mechanisms of Transcriptional Regulation in Prostate Cancer
AACR 2024: First-in-Class Compounds Target MIEN1 Pathway, Have Potential Therapeutic Use
DLL3-Targeting T-Cell Engager Under Study in Neuroendocrine Prostate Cancer
More FORMULA-509 Results After Radical Prostatectomy: Quality-of-Life Outcomes
Long-Term Outcomes Support Image-Guided Therapy for Localized Prostate Cancer
Impact of Metastatic Site on the Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer
Predicting Clinically Significant Prostate Cancer in a Multiethnic Cohort: Novel Blood Assay vs PSA Levels
Combination Therapy Under Study in Metastatic Prostate Cancer With HRR Mutations
Antibiotic Stewardship: Transperineal vs Transrectal Prostate Biopsy
Phase III Trial of Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2024: Cognitive Function With Abiraterone vs Enzalutamide in Metastatic Prostate Cancer
ASCO GU 2024: Dose-Escalation vs Conventional Radiotherapy in High-Risk Prostate Cancer
ASCO GU 2024: Suspending Enzalutamide Monotherapy in High-Risk, Biochemically Recurrent Prostate Cancer
Society of Women in Urologic Oncology Elects Inaugural Chair

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.